Related Experiment Video
Updated: Jun 19, 2026
07:39
The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
Clusterin (CLU) and lung cancer
F Panico1, F Rizzi, L M Fabbri
1Department of Oncology, Hematology and Respiratory Diseases, Section of Respiratory Diseases, University of Modena and Reggio Emilia, 41100 Modena, Italy.
Advances in Cancer Research
|November 3, 2009
Summary
Clusterin (CLU) shows potential as a biomarker in early-stage lung cancer, correlating with better survival. However, its role in advanced stages, particularly in treatment resistance, requires further investigation.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lung cancer remains a leading cause of cancer mortality, with limited therapeutic advancements for advanced disease.
- Nonsmall cell lung cancer (NSCLC) treatment, often involving surgery, still faces challenges with recurrence and survival rates.
- New biomarkers and therapeutic strategies are crucial for improving lung cancer patient outcomes.
Purpose of the Study:
- To investigate the multifaceted role of Clusterin (CLU) in lung cancer progression and treatment response.
- To evaluate CLU as a potential prognostic biomarker in early-stage and advanced NSCLC.
- To explore the therapeutic implications of targeting CLU in lung cancer.
Main Methods:
- In vitro studies using lung cancer cell lines to assess CLU expression and response to chemotherapy and radiotherapy.
- In vivo experiments in animal models to validate in vitro findings.
- Analysis of CLU expression in patient tumors to correlate with clinical outcomes such as overall survival and disease-free survival.
Main Results:
- In vitro studies demonstrated that CLU upregulation after chemo- and radiotherapy may confer cytoprotective effects.
- CLU silencing in vitro sensitized lung cancer cells to treatments and reduced metastatic potential.
- In vivo analysis indicated that CLU-positive NSCLC patients had better survival rates, contrasting with in vitro findings on treatment resistance.
Conclusions:
- Clusterin (CLU) may serve as a positive prognostic biomarker in early-stage NSCLC, associated with improved survival.
- In advanced lung cancer treated with chemo- and radiotherapy, induced CLU might contribute to treatment resistance.
- Further research is essential to elucidate CLU's complex role and to identify patient subgroups that could benefit from CLU-targeting therapies.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:13Pleura of the Lungs
The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
01:47Lung Capacity
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...